Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06154174
Other study ID # 202308160
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 5, 2023
Est. completion date March 2026

Study information

Verified date December 2023
Source Washington University School of Medicine
Contact Mark J Manary, MD
Phone +1 314-454-2341
Email manarymj@wustl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test adding choline to ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition (SAM) in Malawi. The main question it aims to answer is: - Will the addition of a 500mg daily dose of choline to RUTF during treatment for SAM improve cognitive development among 6-59-month-old Malawian children compared with standard RUTF without added choline?


Description:

Severe acute malnutrition (SAM) affects approximately 14 million children worldwide at any one time and has an annual incidence of 3-5x this number. SAM is defined by wasting (mid-upper arm circumference < 11.5 cm or weight-for-length z-score < -3) or presence of bilateral pedal pitting edema. SAM increases short-term risks for infection, hospitalization, and death, as well as longer-term risks for stunted linear growth and impaired cognitive development. This lattermost consequence is increasingly recognized, with studies showing that children who have suffered from SAM score 2-3 standard deviations below age-expected norms on cognitive development tests. Ready-to-use therapeutic food (RUTF) revolutionized SAM treatment by allowing it to occur in the home setting. RUTF cures most children with SAM and ameliorates many of its worst consequences. RUTF was designed to be food-safe and promote anthropometric recovery. Since its inception, evidence has accumulated suggesting that the original fatty acid content of RUTF was not optimized for cognitive recovery from SAM. A 2021 trial, the Improved PUFA Trial (PMID: 34726694), demonstrated that reducing the omega-6 fatty acid content of RUTF and adding docosahexaenoic acid (DHA) improved cognitive development 6 months after SAM treatment in Malawian children. It is possible that further modifications to RUTF's composition might promote greater cognitive recovery. Choline is essential for human health and development and is recognized as such by the Institute of Medicine, which designates daily recommended intakes. Choline deficiency has been shown to induce a host of cognitive developmental problems in animal models, is associated with neural tube defects in humans, and mutations of choline transporters in humans yield developmental degenerative conditions which, while rare, shed light on the essential nature of choline in brain development. Several small randomized, controlled trials have shown benefits of choline supplementation during early life on child cognitive development, both in healthy children and in those exposed to insults such as in fetal alcohol syndrome. Choline plays important roles in brain structure and function and is found primarily in animal-source foods, which are deficient in the diets of children with SAM. Choline is an essential component of the neuronal membrane as well as a precursor for acetylcholine, a key neurotransmitter. In addition, choline plays a role in the trafficking and cell membrane integration of DHA, which rapidly accumulates in the human brain during childhood and ultimately composes 40-50% of brain polyunsaturated fatty acids. Decades of findings from epidemiological studies and laboratory science, including with animal models, support the essential role of DHA in the structure and function of the brain and retina. The Improved PUFA Trial leveraged these insights and showed that the developing brain is sensitive to fatty acid intake in the context of SAM; providing DHA in RUTF improved brain development. Hepatic export of DHA into plasma and its target tissues, including the brain, relies in part on synthesis of phosphatidylcholine (PC) by phosphatidylethanolamine N-methyltransferase (PEMT). DHA-enriched PC molecules (PC-DHA) are generated by PEMT and exported for delivery throughout the body. Indeed, PEMT-deficient mice have reduced DHA plasma concentrations and pups born to PEMT-deficient dams have limited DHA brain accumulation. The PEMT pathway relies on adequate supply of dietary methyl donors such as choline. Pairing (1) choline's ability to increase DHA trafficking to/integration within the brain with (2) the power of DHA in SAM, it is possible that adding choline to RUTF containing DHA might promote cognitive recovery and development among malnourished children. This will be an individually randomized, investigator/outcomes assessors/caregiver-blinded, controlled clinical trial designed to determine whether the addition of a daily dose of 500mg of choline to ready-to-use therapeutic food (C-RUTF) will improve cognitive development among Malawian children 6-59 months of age with SAM compared with standard RUTF (S-RUTF). This trial will be conducted at 10 rural sites in southern Malawi. 1500 children will be randomized 1:1 to receive 2 sachets per day of either C-RUTF or S-RUTF. Children will receive their allocated RUTF and return to clinic fortnightly for repeat anthropometric measurements, illness questions, and to receive more RUTF until they achieve a clinical outcome or for a maximum of 12 weeks, at which point they will undergo Malawi Developmental Assessment Tool (MDAT) testing and blood spot collection. Participants will be asked to return to clinic 5-7 months later for MDAT testing, the global z-score from which will be the trial's primary outcome.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 6 Months to 59 Months
Eligibility Inclusion Criteria: - 6-59 months of age - mid-upper arm circumference < 11.5 cm and/or weight-for-length z-score < -3 and/or presence of bilateral pedal pitting edema - willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic Exclusion Criteria: - features of complicated SAM: inability to tolerate a 30g test dose of RUTF, breathing difficulties, mental status changes, sepsis, or physician/nursing clinical assessment that the child needs immediate hospitalization - participation in a separate feeding program within the past month - known allergy to study food ingredient (peanut, milk, fish) - intention to move away from catchment area within 9 months - developmental delay - presence of a chronic severe medical condition (other than TB and HIV), such as congenital heart disease

Study Design


Intervention

Dietary Supplement:
C-RUTF (Ready-to-Use Therapeutic Food with added choline)
Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
S-RUTF (Ready-to-Use Therapeutic Food without added choline)
Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
Drug:
Amoxicillin
Oral amoxicillin tablets twice per day for 7 days dosed based on weight

Locations

Country Name City State
Malawi Chikonde Chikonde Mulanje
Malawi Chipolonga Chipolonga Machinga
Malawi Makhwira Makhwira Chikwawa
Malawi Mbiza Mbiza Mulanje
Malawi Milonde Milonde Mulanje
Malawi Mitondo Mitondo Chikwawa
Malawi Muloza Muloza Mulanje
Malawi Namasalima Namasalima Mulanje
Malawi Naphimba Naphimba Mulanje
Malawi Nkhate Nkhate Chikwawa

Sponsors (4)

Lead Sponsor Collaborator
Washington University School of Medicine Balchem Corporation, Kamuzu University of Health Sciences, Project Peanut Butter

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Other MDAT global z-score by age Subgroups: enrollment <12 vs. >=12 months of age, -6 to +6, higher scores are better 6-month post-outcome MDAT visit
Other MDAT global z-score by SAM outcome status Subgroups: Recovered vs. Other, -6 to +6, higher scores are better 6-month post-outcome MDAT visit
Primary Malawi Developmental Assessment Tool global z-score Age-standardized score, -6 to +6, higher scores are better 6 months after SAM outcome
Secondary Malawi Developmental Assessment Tool gross motor sub-domain z-score Age-standardized score, -6 to +6, higher scores are better 6 months after SAM outcome
Secondary Malawi Developmental Assessment Tool fine motor sub-domain z-score Age-standardized score, -6 to +6, higher scores are better 6 months after SAM outcome
Secondary Malawi Developmental Assessment Tool language sub-domain z-score Age-standardized score, -6 to +6, higher scores are better 6 months after SAM outcome
Secondary Malawi Developmental Assessment Tool social sub-domain z-score Age-standardized score, -6 to +6, higher scores are better 6 months after SAM outcome
Secondary Malawi Developmental Assessment Tool global z-score Age-standardized score, -6 to +6, higher scores are better Within 1 month of SAM outcome
Secondary Malawi Developmental Assessment Tool gross motor sub-domain z-score Age-standardized score, -6 to +6, higher scores are better Within 1 month of SAM outcome
Secondary Malawi Developmental Assessment Tool fine motor sub-domain z-score Age-standardized score, -6 to +6, higher scores are better Within 1 month of SAM outcome
Secondary Malawi Developmental Assessment Tool language sub-domain z-score Age-standardized score, -6 to +6, higher scores are better Within 1 month of SAM outcome
Secondary Malawi Developmental Assessment Tool social sub-domain z-score Age-standardized score, -6 to +6, higher scores are better Within 1 month of SAM outcome
Secondary Recovery Defined based on enrollment (anthropometric +/- edema) criteria 2-12 weeks of therapeutic feeding
Secondary DHA status Blood spot DHA % of total fatty acids in subset of participants 2-12 weeks of therapeutic feeding (until SAM outcome)
Secondary Time-to-recovery Weeks until recovery criteria met, with recovery defined based on enrollment criteria 2-12 weeks of therapeutic feeding
Secondary Proportion of participants who die Defined by caregiver report 2-12 weeks of therapeutic feeding
Secondary Proportion of participants who die Defined by caregiver report From enrollment to study end (6-month post-SAM-outcome MDAT visit)
Secondary Proportion of participants remaining with SAM Continue to meet SAM criteria after feeding After 12 weeks of therapeutic feeding
Secondary Proportion of participants with kwashiorkor resolution Resolution of nutritional edema 2-12 weeks of therapeutic feeding
Secondary Time-to-kwashiorkor resolution Time to resolution of nutritional edema 2-12 weeks of therapeutic feeding
Secondary Rate of weight gain g/kg/day 2-12 weeks of therapeutic feeding (until SAM outcome)
Secondary Rate of length gain mm/week 2-12 weeks of therapeutic feeding (until SAM outcome)
Secondary Proportion of participants with recurrence of SAM After recovery, again meeting criteria for SAM From recovery until study end (6-month post-SAM-outcome MDAT visit)
Secondary Change in MDAT global z-score Difference in MDAT global z-score between 6-month post-SAM outcome visit and MDAT, global z-score measured within 1 month of SAM outcome, more positive scores are better From MDAT near time of SAM outcome to 6-month post-SAM-outcome MDAT visit
Secondary Proportion of participations requiring hospitalization Safety outcome Enrollment to 6-month post-SAM-outcome MDAT visit)
Secondary Diarrhea Days, reported by caregiver, safety outcome 2-12 weeks of therapeutic feeding (until SAM outcome)
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Recruiting NCT04356924 - Psychological Treatment to Support the Consequences of Cognitive Impairment N/A
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Terminated NCT04493957 - Evaluation of an Educational Program in the Prevention of the Driving Risks in Patients With Neurocognitive Disorders : ACCOMPAGNE N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT04426838 - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad N/A
Completed NCT04713384 - Remote Bimanual Virtual Rehabilitation Post CVD N/A
Recruiting NCT06284213 - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting NCT06053775 - Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP) N/A
Completed NCT03698695 - A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers Phase 1
Not yet recruiting NCT05552729 - Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors Phase 1/Phase 2
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed NCT03187353 - IMProving Executive Function Study Phase 4
Completed NCT03301402 - Air Purifier to Improve Endothelial Function and Carotid Intima Thickness N/A
Completed NCT05395559 - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Recruiting NCT05030285 - Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment N/A
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Recruiting NCT04907565 - Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue